Related references
Note: Only part of the references are listed.Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus
P. Lu et al.
LUPUS (2018)
Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus
Mukul Minocha et al.
CLINICAL PHARMACOKINETICS (2018)
Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers
Ahmed Hamed Salem et al.
CLINICAL DRUG INVESTIGATION (2017)
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Kevin J. Freise et al.
CLINICAL PHARMACOKINETICS (2017)
Antigen-specific immunotherapies in rheumatic diseases
Judit Pozsgay et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Gender balance in patients with systemic lupus erythematosus
Audrey A. Margery-Muir et al.
AUTOIMMUNITY REVIEWS (2017)
New insights into the immunopathogenesis of systemic lupus erythematosus
George C. Tsokos et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation
Kichul Ko et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Bcl-2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupus-Prone Mice and Dampen Interferon-α Production
Yifan Zhan et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Systemic lupus erythematosus
Larissa Lisnevskaia et al.
LANCET (2014)
Autoimmune Rheumatic Diseases 3 Immunopathogenic mechanisms of systemic autoimmune disease
Marie Wahren-Herlenius et al.
LANCET (2013)
Effect of Long-Term Belimumab Treatment on B Cells in Systemic Lupus Erythematosus
Annett M. Jacobi et al.
ARTHRITIS AND RHEUMATISM (2010)
THE ROLE OF APOPTOSIS PROTEINS AND COMPLEMENT COMPONENTS IN THE ETIOPATHOGENESIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
Bernadete L. Liphaus et al.
CLINICS (2010)
The role of B cells in lupus pathogenesis
Emil Nashi et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
Role of Rituximab Therapy in Glomerulonephritis
David Jayne
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
B cells as therapeutic targets in SLE
Inaki Sanz et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
JA Gross et al.
NATURE (2000)
Share Paper
